CEO Michael Metzger Receives Substantial Equity Awards
SNDX has more than doubled off its 52-week low of $8.58.
Summary
Syndax Pharmaceuticals CEO Michael Metzger was granted significant equity awards, including restricted stock units and stock options, totaling approximately $8.99 million.
Key Events · Ownership and Investor Activity · SNDX
-
CEO Granted Significant Equity Awards
CEO Michael Metzger received restricted stock units and stock options valued at approximately $8.99 million, increasing his potential ownership in the company.
-
Routine Tax-Related Share Sale
A sale of 7,412 shares totaling $152,835 occurred to cover tax withholding obligations from RSU vesting, a common practice for equity compensation.
Analysis · SNDX · Life Sciences
This Form 4 filing details a significant equity compensation package for CEO Michael Metzger, comprising restricted stock units (RSUs) and stock options. The awards, valued at approximately $8.99 million, represent a substantial increase in the CEO's potential ownership in the company, aligning his interests with long-term shareholder value. A smaller, routine sale of shares occurred to cover tax withholding obligations related to RSU vesting.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.8% of the 1640 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNDX was trading at $20.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $8.58 to $22.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.